ClinicalTrials.gg
RecruitingNCT04110301Updated Nov 20, 2024

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

A Phase 1/2 interventional study of Recombinant Humanized Monoclonal Antibody MIL62 Injection and Lenalidomide in Follicular Lymphoma and Marginal Zone Lymphoma, sponsored by Beijing Mabworks Biotech Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Beijing Mabworks Biotech Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2019; still recruiting 6 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 147 studies in Lymphoma, Follicular with a site in China — 75 open to participants now, 88 under way, 20 of them phase 3. Lymphoma, Follicular · China.

Planned enrollment
84th of 132
53 · median 93
Started
2019
with 5 others
Phase 1/2
22 of 147
9 open now
Primary completion
2024-01
later than 5 of 87 live
Registered
47th of 147
by date

Among the 147 studies in Lymphoma, Follicular with a site in China, this one is the 84th largest by planned enrollment of the 132 interventional ones that give a count, is one of 6 that started in 2019, is one of 22 in phase 1/2, reaches primary completion later than 5 of the 87 other live ones, and was the 47th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 290 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

75 of the 147 studies in Lymphoma, Follicular with a site in China are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Lymphoma, Follicular with a site in China, or all of them as a file.
02

Study summary

This phase 1b/2 trial studies the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with Relapsed/Refractory low-grade Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL). Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).

Read the detailed description

The Aim of this phase 1b/2 trial (MIL62 Plus Lenalidomide) is to find the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with Relapsed/Refractory low-grade Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL). Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).

03

Conditions studied

  • Follicular Lymphoma and Marginal Zone Lymphoma

Keywords

  • CD20 ,Follicular Lymphoma,Marginal Zone Lymphoma,MIL62
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients, >=18 years of age;
  2. Patients with either documented CD20-positive MZL or FL, WHO grade 1, 2 or 3a
  3. Evidence of progression or lack of response following at least 1 prior treatment
  4. (ECOG) performance status of 0, 1 or 2
  5. At least one bi-dimensionally measurable nodal or tumor lesion defined by CT scan as: greatest transverse diameter > 1.5 cm and a short axis ≥ 10mm
  6. Adequate hematologic function (unless abnormalities are related to NHL)
  7. >6 months
  8. Able and willing to provide written and to comply with the study protocol

Exclusion criteria

Exclusion Criteria:

  1. Evidence ongoing transformation into aggressive NHL
  2. Central nervous system lymphoma
  3. Patients with progressive multifocalleukoencephalopathy (PML)
  4. Prior use of any antibody therapy(except for Rituximab ) within 3 months of study start
  5. Prior use of any anti-cancer vaccine
  6. Prior administration of radiotherapy 42 days prior to study entry
  7. Prior administration of chemotherapy 28 days prior to study entry
  8. History of prior within the last 3 years, with the exception of curatively treated basal or squamous cell carcinoma of the skin and low-grade in situ carcinoma of the cervix
  9. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
  10. Known to thalidomide or lenalidomide
  11. Regular treatment with prior to the start of cycle 1, unless administered for indications other than NHL at a dose equivalent to \< 20 mg/day prednisone
  12. Any serious active disease or co-morbid medical condition (such as Class II or IV cardiac disease, severe arrhythmia, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm or other according to investigator's decision)
  13. Infection with (HIV), or (including HBsAg,HBcAb positive with abnormal HBV DAN or HCV RNA )
  14. Pregnant or lactating females
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (estimated)

Study arms

  • Experimental
    MIL62 + Lenalidomide

    MIL62 plus Lenalidomide

    Drug: Recombinant Humanized Monoclonal Antibody MIL62 Injection · Drug: Lenalidomide

Interventions

  • 1000mg /dose for 12 cycles(28 days) and a total of 11 doses :the first Cycle(Day1,Day15), the 2nd-8th Cycles(Day 1 every cycle);the 9th-12nd Cycles (One dose every two cycles).

    Also known as: MIL62

  • Dose on days 2-22 every 28 days x 12 cycles: the starting dose is 10-mg ; Adjusted dose according to the tumor response or toxicity reaction

    Also known as: Revlimid

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Objective Response of Complete Response

    Percentage of Participants With an Objective Response of Complete Response

    Time frame: Baseline to 1 month after the last dose of last patient

Secondary outcomes

  1. Kaplan-Meier Estimate of Duration of Response

    Kaplan-Meier Estimate of Duration of Response

    Time frame: Baseline to 1 month after the last dose of last patient

  2. Percentage of Participants With Disease Control

    Percentage of Participants With Disease Control

    Time frame: Baseline to 1 month after the last dose of last patient

  3. Participants With 1 Year Progression Free Survival

    Participants With 1 Year Progression Free Survival

    Time frame: Baseline to 1 month after the last dose of last patient

  4. Number of Participants With Treatment Emergent Adverse Events

    Number of Participants With Treatment Emergent Adverse Events

    Time frame: up to the 1 month the last dose of last subject

07

Study locations

1 of 1 sites recruiting
  • Chinese Academy of Medical Sciences and Peking Union Medical College
    Beijing, China
    Recruiting
    • Yuankai Shi, doctor · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Jan 2024, 49 months.

Of 43 industry-sponsored phase 1/2 interventional studies under Lymphoma, Follicular, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 103. This study's 49 months is below that.

Counting every sponsor, half of 88 studies reached it within 73 months; a quarter within 50 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2019
First posted
Oct 1, 2019
StartActual
Nov 28, 2019
Primary completionActual
Jan 9, 2024
CompletionEst.
May 2025
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04110301
Lead sponsor
Beijing Mabworks Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Oct 1, 2019
Start date
Nov 28, 2019
Primary completion
Jan 9, 2024
Completion
May 2025 (estimated)
Last update
Nov 20, 2024

Study contacts

Yuankai Shi, MD
Contact
syuankaipumc@126.com
(+86)010-87788293
Yuankai Shi, MD
principal investigator · Cancer Institute&Hospital, Chinese Academy of Medical Sciences,Beijing

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD20 Monoclonal Antibody MIL62

Start the discussion